Skip to main content
U.S. flag

An official website of the United States government

ASPE Issue Brief

Reports

Displaying 21 - 30 of 290. 10 per page. Page 3.

Advanced Search
ASPE Issue Brief

Health Insurance Coverage and Healthcare Access from 2021-2024

This Issue Brief investigates how health insurance coverage, as well as healthcare access and affordability, has changed in recent years, with an emphasis on policies implemented from 2021 to 2024. Over 300 million Americans now have health insurance coverage. The U.S. uninsured rate has fallen significantly over the past four years.
ASPE Issue Brief

Behavioral Health Service Use Among Medicaid and CHIP Enrollees Before/During the COVID-19 Public Health Emergency

In 2020, 53 million adults in the United States had a mental health condition and 40 million people ages 12 and older had a substance use disorder (SUD). The COVID-19 public health emergency (PHE) exacerbated mental health conditions and SUDs at a time when access to in-person care was restricted due to safety concerns.
ASPE Issue Brief

Operationalizing the Definition of Intellectual and Developmental Disabilities in Administrative Claims Data for Research

The existence of multiple operational definitions for intellectual and developmental disabilities (ID/DD) in analyzing administrative claims data for health services and public health research limits translation of study findings to inform policies, programs, and practice.
ASPE Issue Brief

Treatment for Children and Adolescents Enrolled in Medicaid and CHIP During COVID-19

The first brief below provides insight into children’s and adolescents’ mental health service use in Medicaid and CHIP during the pandemic, by using a national Medicaid claims database.
ASPE Issue Brief

Medicaid Behavioral Health Providers Delivering Most Behavioral Health Services via Telehealth Before and During the COVID-19 Pandemic Issue Brief

The goal of this study was to examine the extent to which Medicaid providers who deliver behavioral health services shifted their practices to mostly tele-behavioral health services during the COVID-19 pandemic.
ASPE Issue Brief, Report

An Evaluation Framework for the Inflation Reduction Act’s Medicare Prescription Drug Related Provisions

The Inflation Reduction Act (IRA) changes the way Medicare pays for prescription drugs. These changes will impact various stakeholders, including Medicare, Medicare enrollees, drug manufacturers, and others.
ASPE Issue Brief

An Examination of the Return on Investment of Generic Injectable Prescription Drugs

The generic injectable drug market has recently experienced numerous shortages, which impose substantial public health costs. One potential cause of these shortages is low profitability of generic injectables. This brief examines the profitability of recently launched generic injectables.
ASPE Issue Brief, Report

Direct Care Worker Wages

Direct care workers (DCWs) such as nursing assistants, home health aides, and personal care assistants play an essential role in the health and well-being of over 20 million Americans. Yet DCW wages are not enough to make jobs competitive with entry level positions in other industries with similar job requirements which exacerbates the challenges in recruitment and retention of these workers.
ASPE Issue Brief

Bridging Healthcare and Social Services for People Living with Dementia and Their Caregivers

People living with dementia often have complex health and social support needs that can best be met by health care and community-based providers working together. This brief examines promising practices for bridging community-based organizations and health care systems in the providing comprehensive dementia care.
ASPE Issue Brief

An Examination of March-in Rights and Drug Products with Government-Interest Patents

March-in authority allows the federal government to grant licenses on privately owned patents for inventions developed with federal funding provided certain statutory requirements are met. It was designed to ensure that the benefits of the American taxpayers’ investment in research and development are reasonably accessible to the public.